English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background: Anemia is the most frequent complication of Chronic Kidney Disease (CKD) which is mainly caused by erythropoietin (Epo) deficiency. Epo agonist is the drug choice for anemia in CKD but some patients have antibody against Epo agonist. Objectives: This study aimed to identify Indonesian medicinal plants that have an agonist activity to Epo receptor in silico. Method: This was a bioinformatics study with using all Indonesian phytochemicals which were registered in HerbalDB and had the 3-D in PubChem. The Epo-EpoR complexes were used as standard ligand and receptor with the Protein Data Bank code 1CN4. Because Epo and EpoR sizes were bigger than 1,500 Da, the molecules were truncated validated 3 times using AutodockVina 1.1.2. and all phytochemicals were molecularly docked using the same method. Docking results were visualized using PyMOL 1.7.4. Results: Truncated Epo interacted with EpoR in 9 different binding sites with average of binding affinity ranging from -2.6 to -5.5 kcal/mol. Indicaxanthin, Miraxanthin-V, and Hexahydrocurcumin had lower binding affinity than standard in each binding sites. Similar binding sites to EpoR were founded in Indicaxanthin. Conclusion: Indicaxanthin, Miraxanthin-V, and Hexahydrocurcumin were potential as Epo agonist in silico to treat anemia in CKD.

Indicaxanthin, Miraxanthin-V, and Hexahydrocurcumin as Potential Erythropoietin Agonist in Silico to Treat Anemia in Chronic Kidney Disease